Published in Blood Weekly, March 11th, 2004
According to their study, "Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2 mg/m2 i.v. daily for 5 days as a continuous infusion limits its use in older patients."
"Therefore, we studied topotecan 1.5 mg/m2 per day i.v. over 2 h for 3 consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL)," wrote D.A. Vaena and colleagues, Indiana University, Division of Hematology & Oncology.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.